Eli Lilly and Company $LLY Stock: Ethic Inc. Boosts Position

Ethic Inc. raised its position in Eli Lilly and Company (NYSE:LLY) by 5.7% during the 3rd quarter, Holdings Channel reports. The firm owned 96,058 shares of the company’s stock after acquiring an additional 5,138 shares during the quarter. Eli Lilly and Company comprises about 1.2% of Ethic Inc.’s holdings, making the stock its 12th biggest position. Ethic Inc.’s holdings in Eli Lilly and Company were worth $111,147,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $13,522,666,000. Jupiter Topco LLC purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $4,667,180,000. Fifth Third Bancorp increased its holdings in Eli Lilly and Company by 321.3% during the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company’s stock valued at $1,805,959,000 after acquiring an additional 1,497,423 shares in the last quarter. Corient Private Wealth LP purchased a new position in Eli Lilly and Company during the 2nd quarter valued at about $764,116,000. Finally, BlackRock Inc. raised its position in Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,372.15 on Friday. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,453.00. The company’s 50-day moving average is $1,215.24 and its two-hundred day moving average is $1,101.16. The firm has a market cap of $1.29 trillion, a price-to-earnings ratio of 44.54, a price-to-earnings-growth ratio of 1.69 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue for the quarter was up 38.6% on a year-over-year basis. During the same period in the previous year, the company earned $7.02 EPS. Research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is 22.46%.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the sale, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $17,020,770 over the last quarter. 0.14% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent research reports. Berenberg Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a report on Tuesday, September 15th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Argus upped their target price on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research note on Friday, October 30th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,650.00 target price on shares of Eli Lilly and Company in a research note on Friday, October 30th. Finally, Scotiabank increased their target price on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $1,404.14.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.